{"id":"d27bde006579","type":"article","url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","title":"Ventriculaire aritmie bij niet-ischemisch HF: prevalentie en prognose — DANISH","title_en":"Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["nt-probnp"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaa341","source_url":"https://doi.org/10.1093/europace/euaa341","authors":["Rune Boas","Jens Jakob Thune","Steen Pehrson","Lars Køber","Jens C Nielsen","Lars Videbæk","Jens Haarbo","Eva Korup","Niels Eske Bruun","Axel Brandes","Hans Eiskjær","Anna M Thøgersen","Berit T Philbert","Jesper Hastrup Svendsen","Ulrik Dixen"],"significance":6,"published":"2021-04-06","source_date":"2021-04-06","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This DANISH analysis characterized the prevalence and prognostic significance of ventricular arrhythmias in non-ischemic heart failure, providing risk stratification data for ICD selection in this debated indication.","created":"2026-07-03T10:29:08Z","updated":"2026-07-03T13:28:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"DANISH analyse naar prevalentie en prognostische associatie van ventriculaire aritmieën bij niet-ischemisch hartfalen.","abstract_original":"AIMS: Improved risk stratification to identify non-ischaemic heart failure patients who will benefit from primary prophylactic implantable cardioverter-defibrillator (ICD) is needed. We examined the potential of ventricular arrhythmia to identify patients who could benefit from an ICD. METHODS AND RESULTS: A total of 850 non-ischaemic systolic heart failure patients with left ventricle ≤35% and elevated N-terminal pro-brain natriuretic peptides had a 24-h Holter monitor recording performed. We examined present non-sustained ventricular tachycardia (NSVT), defined as ≥3 consecutive premature ventricular contractions (PVCs) with a rate of ≥100/min, and number of PVCs per hour stratified into low (<30) and high burden (≥30) groups. Outcome measures were overall mortality, sudden cardiac death (SCD), and cardiovascular death (CVD). In total, 193 patients died, 49 from SCD and 125 from CVD. Non-sustained ventricular tachycardia (365 patients) was significantly associated with increased all-cause mortality [hazard ratio (HR) 1.47; 95% confidence interval (CI) 1.07-2.03; P = 0.02] and to CVD (HR 1.89; CI 1.25-2.87; P = 0.003). High burden PVC (352 patients) was associated with increased all-cause mortality (HR1.38; CI 1.00-1.90; P = 0.046) and with CVD (HR 1.78; CI 1.19-2.66; P = 0.005). There was no statistically significant association with SCD for neither NSVT nor PVC. In interaction analyses, neither NSVT (P = 0.56) nor high burden of PVC (P = 0.97) was associated with survival benefit from ICD implantation. CONCLUSION: Ventricular arrhythmia in non-ischaemic heart failure patients was associated with a worse prognosis but could not be used to stratify patients to ICD implantation."}